Analytical Data
-
Gene name
GPR119
- Application
-
Alternative Names
GPR119; Glucose-dependent insulinotropic receptor; G-protein coupled receptor 119
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TDV5
-
Expression Region
236-335aa
-
AA Sequence
LSWTPFLITGIVQVACQECHLYLVLERYLWLLGVGNSLLNPLIYAYWQKEVRLQLYHMALGVKKVLTSFLLFLSARNCGPERPRESSCHIVTISSSEFDG
-
Molecular Weight
36.63 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPR119 is a G protein-coupled receptor that has garnered significant attention in the field of metabolic research due to its role in glucose homeostasis and insulin secretion. It is primarily expressed in the pancreas and gastrointestinal tract, where it plays a crucial role in mediating the effects of various gut-derived incretin hormones, such as GLP-1 and GIP. The activation of GPR119 has been shown to stimulate insulin secretion in a glucose-dependent manner, making it a promising target for the development of new therapies for type 2 diabetes and obesity. Furthermore, studies have indicated that GPR119 may also influence lipid metabolism and promote satiety, further highlighting its potential in addressing metabolic disorders. The generation of recombinant GPR119 proteins is essential for detailed biochemical and pharmacological studies, enabling researchers to elucidate its signaling mechanisms, structure-activity relationships, and interactions with potential ligands. By developing GPR119 as a therapeutic target, there is hope for novel interventions that can improve glycemic control and enhance metabolic health, ultimately contributing to better management strategies for individuals suffering from metabolic diseases.
